By Counterforce Health Team in Garadacimab (anti-FXIIa) — FDA-approved 2025 —

How to Get Garadacimab (Andembry) Covered by Humana in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Garadacimab Covered by Humana in North Carolina

Garadacimab (Andembry) requires prior authorization from Humana and faces step therapy requirements. You must document failed trials with preferred HAE prophylaxis medications first. Standard PA decisions take 30 days (72 hours expedited). If denied, Humana Medicare Advantage uses federal appeals; commercial plans can use North Carolina's Smart NC external review. Start today: Contact your specialist to begin documenting prior therapy failures and request the Humana PA form.

Table of Contents

  1. Coverage Basics
  2. Prior Authorization Process
  3. Timing and Deadlines
  4. Medical Necessity Criteria
  5. Cost Considerations
  6. Denials and Appeals
  7. Authorization Renewals
  8. Specialty Pharmacy Requirements
  9. Troubleshooting Common Issues
  10. Frequently Asked Questions

Coverage Basics

Is Garadacimab Covered by Humana?

Garadacimab (brand name Andembry) is covered by Humana plans but requires prior authorization. The medication is not automatically approved and faces mandatory step therapy requirements before coverage begins.

Which Humana Plans Cover It?

  • Medicare Advantage: Covered under Part B as a specialty injectable medication
  • Commercial Plans: Subject to formulary placement and prior authorization
  • Medicare Part D: May require formulary exception if not listed
Note: Coverage varies by specific plan. Verify your benefits by calling the member services number on your insurance card.

Formulary Status

On Humana's 2025 formulary, garadacimab may require a formulary exception request with medical necessity documentation if not listed as a covered drug. Patients can request exceptions by demonstrating that covered alternatives are inappropriate for their specific case.

Prior Authorization Process

Who Submits the Request?

Your prescribing physician (typically an allergist, immunologist, or hematologist) must submit the prior authorization request through Humana's provider portal or by calling 1-866-488-5995 for Medicare requests regarding professionally administered drugs.

Required Documentation Checklist

HAE Diagnosis Confirmation:

  • C4 levels (invariably low in HAE)
  • C1-INH quantitative and functional levels
  • Genetic testing results (if available for HAE with normal C1-INH)
  • Clinical documentation of recurrent angioedema episodes

Prior Therapy Documentation:

  • Failed trials with preferred drugs (Haegarda, Takhzyro, or C1-INH products)
  • Specific reasons for discontinuation or contraindications
  • Duration of each trial and clinical outcomes

Clinical Necessity:

  • Attack frequency logs documenting ≥2 attacks per month
  • Specialist prescription from board-certified provider
  • Medical necessity justification explaining why garadacimab's anti-FXIIa mechanism is necessary

How to Check Status

Log into your Humana member portal or have your provider check the authorization status through their provider portal. You can also call member services for updates.

Timing and Deadlines

Request Type Timeline When to Use
Standard PA 30 days Routine requests
Expedited PA 72 hours Health at immediate risk
Medicare Part D Exception 72 hours Standard formulary exceptions

What Qualifies as Urgent?

Expedited reviews are available when delays would seriously jeopardize your health or ability to regain function. For HAE patients, this might include:

  • Recent increase in attack frequency
  • Hospitalization due to laryngeal swelling
  • Failed current prophylaxis with breakthrough attacks

Medical Necessity Criteria

Step Therapy Requirements

Before approving garadacimab, Humana requires documentation of failed trials or contraindications with preferred HAE prophylaxis medications:

Preferred Alternatives (must try first):

  • Haegarda (C1-INH subcutaneous)
  • Takhzyro (lanadelumab)
  • Cinryze (C1-INH intravenous)
  • Orladeyo (berotralstat)

Laboratory Requirements for HAE Diagnosis

The diagnosis requires specific blood tests with the following patterns:

  • C4 levels: Low (most useful screening test)
  • C1-INH quantitative: Low in Type I HAE, normal/high in Type II
  • C1-INH functional: Low in both Type I and II HAE
Clinician Corner: When low C4 levels are combined with low C1-INH function, diagnostic accuracy reaches 98%. Blood samples should be handled carefully to avoid decay of functional C1-INH.

Attack Frequency Documentation

Maintain detailed logs showing:

  • Date and time of each attack
  • Location of swelling (face, throat, extremities, abdomen)
  • Duration and severity
  • Triggers (if identifiable)
  • Treatment required (emergency care, medications)

Cost Considerations

Copay and Coinsurance

Garadacimab is dispensed through specialty pharmacies, which may have different cost-sharing than regular medications:

  • Medicare Part B: Typically 20% coinsurance after deductible
  • Commercial Plans: Varies by plan design and formulary tier

Patient Support Programs

Contact CSL Behring's patient assistance program for potential copay support options. The manufacturer may offer financial assistance for eligible patients.

Specialty Pharmacy Network

CenterWell Specialty Pharmacy is the preferred vendor for Humana patients, though specific network details should be verified with member services.

Denials and Appeals

Common Denial Reasons and Solutions

Denial Reason How to Address
Lack of confirmed HAE diagnosis Submit complete lab results (C4, C1-INH levels)
Insufficient prior therapy trials Document specific failures/contraindications with preferred drugs
Missing specialist evaluation Obtain prescription from allergist, immunologist, or hematologist
Incomplete attack documentation Provide detailed frequency logs and clinical notes

Appeal Process for Different Plan Types

Humana Medicare Advantage:

  • Internal Appeal: 65 days from denial notice
  • External Review: Through Independent Review Organization (IRO)
  • Timeline: Standard appeals within 30 days, expedited within 72 hours

Commercial Humana Plans in North Carolina:

  • Internal Appeal: Follow Humana's two-level process
  • External Review: Through North Carolina's Smart NC program
  • Timeline: 120 days to request external review, 45-day decision

North Carolina External Review Rights

For commercial Humana plans, North Carolina offers strong consumer protections through Smart NC:

Contact Information:

  • Phone: 1-855-408-1212
  • Free advocacy and guidance through the appeals process

Process:

  1. Complete Humana's internal appeals first
  2. Submit External Review Request Form within 120 days
  3. Independent Review Organization provides decision within 45 days
  4. Expedited reviews available within 72 hours for urgent cases
Important: Smart NC does not apply to Medicare Advantage plans, which must use federal appeals processes.

Authorization Renewals

When to Reauthorize

Prior authorizations for specialty biologics typically require renewal every 6-12 months. Your specialty pharmacy will notify you before expiration.

What Documentation Changes?

Renewal requests should include:

  • Updated attack frequency logs
  • Current clinical assessment
  • Confirmation that alternative therapies remain inappropriate
  • Any changes in dosing or administration

Specialty Pharmacy Requirements

Why Was My Prescription Transferred?

Garadacimab must be dispensed through specialty pharmacies due to:

  • Cold storage requirements
  • Patient training for self-injection
  • Coordination with patient support programs
  • Insurance network requirements

What to Expect

Specialty pharmacies provide:

  • Delivery coordination
  • Injection training and support
  • Prior authorization assistance
  • Copay program enrollment

Troubleshooting Common Issues

Provider Portal Problems

If your doctor cannot access Humana's prior authorization portal:

  • Verify provider enrollment status
  • Use alternative submission methods (fax, phone)
  • Contact provider services for technical support

Missing Forms or Documentation

Common missing items include:

  • Complete lab results with reference ranges
  • Detailed prior therapy documentation
  • Specialist evaluation notes
  • Attack frequency logs

Communication Delays

To avoid delays:

  • Submit complete documentation initially
  • Respond promptly to requests for additional information
  • Use expedited processes when clinically appropriate

Frequently Asked Questions

How long does Humana prior authorization take in North Carolina? Standard requests take up to 30 days, while expedited requests are completed within 72 hours if health is at risk.

What if garadacimab is non-formulary on my plan? You can request a formulary exception by demonstrating medical necessity and showing that covered alternatives are inappropriate.

Can I request an expedited appeal? Yes, if delays would seriously jeopardize your health. For HAE patients, this includes situations with increased attack frequency or breakthrough attacks on current therapy.

Does step therapy apply if I failed medications outside North Carolina? Yes, documented failures from other states count toward step therapy requirements if properly documented in your medical records.

What happens if my appeal is denied? For commercial plans, you can request external review through Smart NC. For Medicare Advantage, you can appeal to an Independent Review Organization.

How do I prove medical necessity? Provide complete HAE diagnosis confirmation, documented failures with preferred therapies, attack frequency logs, and specialist evaluation explaining why garadacimab is specifically needed.

From Our Advocates

We've seen HAE patients successfully appeal denials by focusing on the unique mechanism of garadacimab compared to other prophylaxis options. The key is demonstrating that traditional C1-INH therapies haven't provided adequate attack prevention, making the anti-FXIIa approach medically necessary. Detailed attack logs showing breakthrough episodes despite optimal dosing of preferred therapies often strengthen these cases significantly.

Counterforce Health specializes in turning insurance denials into successful appeals by creating evidence-backed, payer-specific responses. Our platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements by identifying denial reasons and drafting targeted rebuttals aligned with each plan's specific criteria. Learn more about our coverage advocacy services.

When facing a garadacimab denial, Counterforce Health can help build a compelling appeal that addresses Humana's specific requirements while incorporating the clinical evidence and procedural details that payers expect for specialty biologic approvals.

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies change frequently. Always verify current requirements with your insurance plan and consult your healthcare provider for medical decisions.

Need Help? Contact Smart NC at 1-855-408-1212 for assistance with North Carolina insurance appeals, or reach out to your healthcare provider for clinical guidance.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.